Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications
Summary: Immune checkpoint therapy targeting PD-L1/PD-1 represents a key cancer treatment strategy. PD-L1 binds PD-1 on T cells, suppressing activation and enabling tumor immune escape. Although the blockade of the PD-L1/PD-1 pathway has demonstrated significant anti-tumor effects, the overall respo...
Saved in:
| Main Authors: | Yifei Zhang, Keyu Yin, Runsheng Ma, Yuxiao Sun, Longlong Wang, Detao Yin |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004225008764 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gene-regulatory programs that specify age-related differences during thymocyte development
by: Divya Ganapathi Sankaran, et al.
Published: (2025-07-01) -
Growth of human regulatory CD4+ T cells is more tightly controlled than effector T cells due to distinctive molecular programming
by: Alejandro Moro, et al.
Published: (2025-06-01) -
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
by: Esdy N. Rozali, et al.
Published: (2012-01-01) -
Ocular immune privilege in action: The living eye imposes unique regulatory and anergic gene signatures on uveitogenic T cells
by: Zixuan Peng, et al.
Published: (2025-06-01) -
Regulatory T cells suppress GM-CSF-producing T helper cells via IL-2 modulation to restrain immunopathology
by: Sara Costa-Pereira, et al.
Published: (2025-05-01)